lactic acid has been researched along with Leishmaniasis, Cutaneous in 9 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Leishmaniasis, Cutaneous: An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We found that MMWC was toxic for two parasite forms." | 1.39 | In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study. ( Barbosa, H; Delgado, G; Gutiérrez, J; Pinzón, J; Vallejo, B, 2013) |
| " For this, AMB nanoencapsulated in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles (Nano-D-AMB) has been developed, and its efficacy was evaluated in the treatment of experimental cutaneous leishmaniasis in C57BL/6 mice, to test if our nano-drug delivery system could favor the reduction of the dose frequency required to achieve the same therapeutic level of free D-AMB, and so, an extended dosing interval." | 1.39 | Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. ( Báo, SN; Cintra e Silva, Dde O; de Carvalho, RF; de Souza Filho, J; Lacava, ZG; Martins, OP; Miranda-Vilela, AL; Ribeiro, IF; Sampaio, RN; Tedesco, AC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sousa-Batista, AJ | 1 |
| Arruda-Costa, N | 1 |
| Rossi-Bergmann, B | 1 |
| Ré, MI | 1 |
| Noormehr, H | 1 |
| Zavaran Hosseini, A | 1 |
| Soudi, S | 1 |
| Beyzay, F | 1 |
| Gutiérrez, J | 1 |
| Vallejo, B | 1 |
| Barbosa, H | 1 |
| Pinzón, J | 1 |
| Delgado, G | 1 |
| Navaei, A | 1 |
| Rasoolian, M | 1 |
| Momeni, A | 1 |
| Emami, S | 1 |
| Rafienia, M | 1 |
| de Carvalho, RF | 1 |
| Ribeiro, IF | 1 |
| Miranda-Vilela, AL | 1 |
| de Souza Filho, J | 1 |
| Martins, OP | 1 |
| Cintra e Silva, Dde O | 1 |
| Tedesco, AC | 1 |
| Lacava, ZG | 1 |
| Báo, SN | 1 |
| Sampaio, RN | 1 |
| Santos, DM | 1 |
| Carneiro, MW | 1 |
| de Moura, TR | 1 |
| Fukutani, K | 1 |
| Clarencio, J | 1 |
| Soto, M | 1 |
| Espuelas, S | 1 |
| Brodskyn, C | 1 |
| Barral, A | 1 |
| Barral-Netto, M | 1 |
| de Oliveira, CI | 1 |
| Pinto, MC | 1 |
| Bray, DP | 1 |
| Eiras, AE | 1 |
| Carvalheira, HP | 1 |
| Puertas, CP | 1 |
| SILVESTRI, U | 1 |
| Piñero, J | 1 |
| Temporal, RM | 1 |
| Silva-Gonçalves, AJ | 1 |
| Jiménez, IA | 1 |
| Bazzocchi, IL | 1 |
| Oliva, A | 1 |
| Perera, A | 1 |
| Leon, LL | 1 |
| Valladares, B | 1 |
9 other studies available for lactic acid and Leishmaniasis, Cutaneous
| Article | Year |
|---|---|
Improved drug loading via spray drying of a chalcone implant for local treatment of cutaneous leishmaniasis.
Topics: Chalcones; Drug Carriers; Drug Compounding; Lactic Acid; Leishmaniasis, Cutaneous; Microspheres; Par | 2018 |
Enhancement of Th1 immune response against Leishmania cysteine peptidase A, B by PLGA nanoparticle.
Topics: Adjuvants, Immunologic; Animals; Cysteine Proteases; Female; Interferon-gamma; Interleukin-4; Lactic | 2018 |
In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study.
Topics: Antiprotozoal Agents; Cell Line; Cell Survival; Chitosan; Cicatrix; Drug Carriers; Excipients; Fibro | 2013 |
Double-walled microspheres loaded with meglumine antimoniate: preparation, characterization and in vitro release study.
Topics: Antiprotozoal Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Carriers; | 2014 |
Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Biological Availability; Drug Delivery Systems; Drug | 2013 |
Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Cytokines; Drug Delivery Systems; Female; Immun | 2012 |
Attraction of the cutaneous leishmaniasis vector Nyssomyia neivai (Diptera: Psychodidae) to host odour components in a wind tunnel.
Topics: Animals; Behavior, Animal; Chemotactic Factors; Disease Vectors; Entomology; Female; Lactic Acid; Le | 2012 |
[Use of lactate of 2 ethoxy-6,9-diaminoacridine (rivanol) in cutaneous leishmaniasis].
Topics: Acridines; Coloring Agents; Ethacridine; Lactates; Lactic Acid; Leishmaniasis; Leishmaniasis, Cutane | 1951 |
New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis.
Topics: Absorbable Implants; Animals; Antiprotozoal Agents; Chalcone; Drug Therapy, Combination; Lactic Acid | 2006 |